Study guide

16.3 Toxin and Drug Exposure, NAS, and FASD

CCRN Neonatal Critical Care Certification Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction and Exam Overview

1.1 Current Exam Facts 1.2 Eligibility, Retakes, and Renewal 1.3 Synergy Model, Blueprint Weights, and NICU Foundations

2 Cardiovascular: Transition and Congenital Disease

2.1 Fetal Circulation, PDA, PFO, and Transitional Physiology 2.2 Congenital Heart Defects 2.3 Neonatal Cardiac Surgery and Postoperative Care

3 Cardiovascular: Instability and Rhythm

3.1 Hemodynamic Instability, Monitoring, and Vascular Access 3.2 Heart Failure, Tamponade, and Acquired Cardiac Conditions 3.3 Neonatal Dysrhythmias and Cardioversion

4 Respiratory: Transition, RDS, Failure, and Apnea

4.1 RDS, Surfactant, TTN, and Transitional Respiratory Failure 4.2 Acute Respiratory Distress, Failure, and Assisted Ventilation 4.3 Apnea of Prematurity

5 Respiratory: Aspiration, Chronic Lung Disease, Anomalies, and PPHN

5.1 Aspiration and Meconium Aspiration Syndrome 5.2 Chronic Lung Disease, BPD, and Pulmonary Interstitial Emphysema 5.3 Congenital Respiratory Anomalies and Surgery 5.4 PPHN, Pulmonary Hemorrhage, Pleural Disease, and Infection

6 Endocrine Disorders

6.1 Neonatal Glucose Homeostasis 6.2 Calcium, Thyroid, and Adrenal Disorders 6.3 Metabolism Disorders and Inborn Errors

7 Hematology and Immunology

7.1 Anemia, Polycythemia, Sickle Cell, and Leukopenia 7.2 Coagulopathies, DIC, Thrombocytopenia, and Factor Deficiencies 7.3 Hemolytic Disease of the Newborn

8 Gastrointestinal Disorders

8.1 Congenital and Acquired GI Abnormalities 8.2 Necrotizing Enterocolitis 8.3 Nutrition, Feeding Intolerance, Malabsorption, GER, and Lactation 8.4 Hepatic Failure, Biliary Atresia, and Cholestasis

9 Renal, Genitourinary, and Integumentary Care

9.1 Congenital and Acquired Renal and GU Conditions 9.2 Gestational-Age Skin, TEWL, Humidity, and Congenital Skin Conditions 9.3 Infiltration, Wounds, Diaper Dermatitis, and Skin Infection

10 Musculoskeletal Conditions and Congenital Neurology

10.1 Acquired and Congenital Musculoskeletal Conditions 10.2 Congenital Neurologic Abnormalities and Surgery 10.3 Neonatal Seizures and CNS Infection

11 Neurologic Injury, Neuroprotection, and Infant State

11.1 IVH and Extra/Intracranial Hemorrhage 11.2 HIE, PVL, Stroke, and Therapeutic Hypothermia 11.3 Pain, Sedation, and State Dysregulation

12 Behavioral and Psychosocial Care in the NICU

12.1 Family Systems, Engagement, and Caregiver Confidence 12.2 Families in Crisis, Grief, and Escalation 12.3 Culture, Communication, Language, Abuse, and Neglect

13 Multisystem: Homeostasis

13.1 Acid-Base and Fluid/Electrolyte Imbalance 13.2 Thermoregulation 13.3 Hyperbilirubinemia 13.4 Infant of a Diabetic Mother

14 Multisystem: Sepsis, Shock, and Hospital-Acquired Harm

14.1 Early- and Late-Onset Sepsis 14.2 Shock States 14.3 Healthcare-Acquired Conditions and Multi-Organ Failure

15 Multisystem: Perinatal Injury and Genetic Conditions

15.1 Birth Trauma and Hydrops Fetalis 15.2 Life-Threatening Maternal/Fetal Complications 15.3 Genetic Conditions, Syndromes, and Trisomies 15.4 Sequences: VACTERL and Pierre Robin

16 Multisystem: Advanced Support and Continuum of Care

16.1 ECMO, CRRT, Dialysis, and Other Advanced Therapies 16.2 Growth, Developmental Delay, and Sensory Impairment 16.3 Toxin and Drug Exposure, NAS, and FASD 16.4 Terminal Conditions, Palliative Care, and End of Life

17 Professional Caring: Advocacy through Collaboration

17.1 Advocacy and Moral Agency 17.2 Caring Practices 17.3 Clinical Inquiry 17.4 Collaboration

18 Professional Caring: Learning, Diversity, and Systems Thinking

18.1 Facilitation of Learning 18.2 Response to Diversity 18.3 Systems Thinking

16.3 Toxin and Drug Exposure, NAS, and FASD

Key Takeaways Explain This Topic AI

Finnegan-style tools tally withdrawal signs to a numeric score; Eat, Sleep, Console judges whether the infant can eat, sleep, and be consoled—both approaches are in use.

Nonpharmacologic care (rooming-in, low stimulation, feeding) is first-line; when medicine is needed, morphine or methadone is stabilized then weaned by about 10–20 percent, with a post-discontinuation watch.

Late-pregnancy SSRI exposure can cause poor neonatal adaptation that is usually time-limited and supportive—it is not treated as opioid NAS with a morphine wean.

FASD sentinel facial features are short palpebral fissures, a smooth philtrum, and a thin upper lip, together with CNS and often growth findings after prenatal alcohol exposure.

Days of NICU opioid or benzodiazepine infusion create iatrogenic withdrawal, a planned-wean problem distinct from in-utero NAS.

Last updated: September 2026

16.3 Toxin and Drug Exposure, NAS, and FASD

Quick Answer: Neonatal opioid withdrawal is managed first with low-stimulation, caregiver-present care. Finnegan-style scoring tallies signs; Eat, Sleep, Console (ESC) asks whether the infant can eat, sleep, and be consoled—both exist. If medicine is needed, morphine or methadone is weaned after a stable period. Maternal SSRIs cause poor neonatal adaptation, usually supportive. FASD is prenatal alcohol injury with sentinel facial features plus brain and often growth findings. Iatrogenic opioid withdrawal follows days of NICU infusions and needs a planned wean.

Toxin and drug exposure is a Multisystem leaf because the infant in front of you may be withdrawing from methadone, jittery from an SSRI, dysmorphic from alcohol, or tachycardic from a fentanyl drip you started last week. The wrong label produces the wrong drug.

Opioid exposure: NAS and NOWS

Neonatal abstinence syndrome (NAS) is the older umbrella for withdrawal after in-utero drug exposure. Neonatal opioid withdrawal syndrome (NOWS) names the opioid-specific picture: high muscle tone, tremors, exaggerated Moro, sweating, mottling, stuffy nose, tachypnea, poor feeding, vomiting, diarrhea, and a high-pitched cry. Onset depends on the opioid's half-life. Short-acting heroin or oxycodone often declares in the first 24–48 hours. Methadone and buprenorphine used as medications for opioid use disorder may peak later (methadone often 48–72 hours, sometimes longer), which is why a 24-hour stay is not a withdrawal clearance. Polysubstance exposure (benzodiazepines, gabapentin, nicotine) muddies the timeline.

Toxicology (umbilical, meconium, urine) can support the history; it does not grade severity. Stigma-free language matters clinically: a mother in treatment is not a discharge obstacle by default. Breastfeeding is often appropriate when she is stable on methadone or buprenorphine, not using illicit drugs, and HIV-negative, because human milk and rooming-in are among the strongest nonpharmacologic therapies you have.

Two assessment cultures: Finnegan and ESC

You must be able to describe both, because units still use both.

The Finnegan Neonatal Abstinence Scoring System (and modified versions) assigns points to signs across CNS, metabolic/vasomotor, and gastrointestinal clusters. Scores are typically taken every 3–4 hours. Pharmacotherapy thresholds are protocol-specific; classic teaching used clustered high scores (for example three scores ≥8 or two ≥12) as a trigger. The strength is a shared numeric language. The weakness is that a hungry, loudly crying infant in a bright, noisy nursery can be scored into morphine that a swaddled infant in a dark room with a parent would never have needed.

The Eat, Sleep, Console approach is a functional model. A well-managed infant eats an adequate volume or latches effectively, sleeps about an hour or more at a stretch, and can be consoled within a short interval (often taught as about 10 minutes). If those functions fail despite maximized nonpharmacologic care, medicine is considered. ESC is bundled with rooming-in, parent presence as treatment, clustered cares, and a quiet environment. In the multicenter ESC-NOW cluster trial, infants managed with ESC reached medical readiness for discharge in about 8.2 days versus 14.9 days with usual Finnegan-based care, with similar measured safety outcomes. That trial does not make Finnegan illegal, and later observational work has suggested that if the rest of the care model is already family-centered, swapping only the score sheet may not move outcomes by itself. Exam takeaway: both approaches exist ; ESC is function-first; Finnegan is sign-tally; nonpharmacologic care is not optional decoration in either.

Nonpharmacologic stack, in order of how much it usually moves the infant:

  • Parent or consistent caregiver in the room, skin-to-skin
  • Dark, quiet, swaddled, clustered handling
  • On-demand feeding, including breastfeeding when appropriate
  • Pacifier, rocking, a single voice rather than a crowd
  • Treat hunger, soiled diapers, and nasal congestion before you treat withdrawal
  • Morphine and methadone weans, conceptually

When function still fails, a first-line opioid is started. Morphine is short-acting and usually given every 3–4 hours (sometimes as a continuous infusion in intensive cases). After a stable interval (often 24–48 hours of good function or acceptable scores), wean by about 10–20 percent of the stabilizing dose every 24 hours as tolerated. Observe 24–48 hours off morphine before discharge in many protocols.

Methadone lasts longer, so dosing intervals are wider and some comparative studies show shorter length of stay. Weans are often about 10 percent once daily after stability. Observe 48–72 hours off methadone (longer if the treatment course was many days). Phenobarbital or clonidine may be adjuncts for polysubstance or autonomic storming; they are not first-line for straightforward opioid withdrawal in most modern protocols. Do not memorize a single national milligram-per-kilogram as if every hospital uses it—the testable idea is stabilize, then wean slowly, then watch after the last dose . Discharging an infant home on an opioid wean is uncommon and requires a clinician who actually does that work in clinic.

Adjunct comfort does not include as-needed naloxone for in-utero opioid exposure; precipitating acute withdrawal in a chronically exposed neonate is harmful.

  • Topic Finnegan-style ESC
  • What is scored Discrete withdrawal signs Ability to eat, sleep, and be consoled
  • Typical cadence Every 3–4 hours Each care interval, function-focused
  • First-line treatment Nonpharmacologic care still required Nonpharmacologic care is the treatment
  • When medicine starts Clustered high scores per protocol Function fails despite maximized supportive care
  • Trial signal Longer stays in usual-care arms of ESC-NOW About 8.2 vs 14.9 days to readiness in ESC-NOW
  • Maternal SSRIs are not opioid NAS

Selective serotonin reuptake inhibitors taken in late pregnancy are associated with poor neonatal adaptation (also called delayed neonatal adaptation): jitteriness, irritability, tachypnea or a need for a brief oxygen or CPAP period, feeding difficulty, hypoglycemia, and tone changes. Symptoms cluster in the first 48–72 hours and are usually time-limited. This is not a mandate to start morphine, and it is not FASD. Treat glucose, temperature, and respiratory transition. A small fraction look more ill; evaluate for sepsis and hypoglycemia the same way you would for any jittery neonate. Historical concern about SSRI-associated PPHN should not send every exposed infant to iNO; recent adjusted analyses have not shown a clear PPHN or nitric-oxide signal. Do not advise abrupt maternal cessation of needed antidepressants as neonatal prevention—maternal depression is also a neonatal risk.

FASD features

Fetal alcohol spectrum disorders (FASD) result from prenatal alcohol exposure. There is no known safe amount or safe trimester. Sentinel facial features taught across guidelines are:

  • Short palpebral fissures
  • Smooth philtrum
  • Thin upper vermilion border

Growth deficiency and CNS involvement (microcephaly, later executive-function and behavioral disability, sometimes structural brain anomalies) complete the picture used in older fetal-alcohol-syndrome definitions. Newer diagnostic schemas can diagnose FASD with three sentinel features plus severe neurodevelopmental impairment even when the exposure history is incomplete, but that work is usually done by a specialist team, not by a night-shift gestalt. In the NICU you document measurements, photograph carefully if the family consents, take a nonjudgmental alcohol history, and refer. Differential includes genetic syndromes that mimic the midface; that is why genetics (Chapter 15) and this toxin chapter talk to each other. Cardiac and renal anomalies can coexist. Stigma shuts down history; curiosity keeps the infant in follow-up.

Iatrogenic opioid withdrawal after infusions

A 5-day fentanyl infusion for a ventilated infant is a different disease from maternal oxycodone. After several days of continuous opioid or benzodiazepine, expect iatrogenic withdrawal if you stop cold. PICU-derived tools such as WAT-1 are used in some neonatal units; others adapt NAS scores. The treatment is a planned wean (often 10–20 percent per day, slower after long exposure), sometimes with clonidine or a conversion to methadone for a smoother tail. Dexmedetomidine infusions create their own discontinuation syndrome. Label the problem correctly on the handoff: this infant's tremors started when the drip was cut in half, not at 6 hours of life.

Worked scenario

Infant A is 39 weeks, mother on buprenorphine, rooming-in, breastfeeding. The infant eats 30 mL, sleeps 90 minutes, and settles in 5 minutes. ESC says continue nonpharmacologic care; starting morphine because a single Finnegan score was 9 in a noisy treatment room is the exam trap.

Infant B is 34 weeks, postoperative CDH, fentanyl 2 micrograms/kg/hour for 8 days. The drip is stopped at extubation and 6 hours later the infant is sweaty, tachycardic, and diarrhea-soaked. That is iatrogenic withdrawal: restart a low infusion or give a wean plan, not a lecture about maternal drug use.

  • Exam traps
  • Believing only Finnegan or only ESC is real
  • Morphine-first before maximizing caregiver presence
  • Treating SSRI jitter as opioid NAS
  • Diagnosing FASD from a thin lip alone
  • Abruptly stopping a week-long fentanyl infusion